Cardiac implantable electronic device-detected atrial fibrillation —“To anticoagulate or not to anticoagulate, that is the question”: The noble or ignoble choice?

Atrial fibrillation (AF) detected during interrogation of a cardiovascular implantable electronic device (CIED) is a common event,1 with available studies suggesting that it is associated with an increased risk of stroke.2,3 While current guidelines recommend oral anticoagulant (OAC) therapy for patients with AF and an elevated CHA2DS2-VASc score,4 controversy exists about whether the various components of CIED-detected AF (eg, duration, burden, and CHA2DS2-VASc score) predict stroke and, if effective as predictors, which characteristics best define that risk.
Source: Heart Rhythm - Category: Cardiology Authors: Tags: Editorial Commentary Source Type: research